OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+15.55%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$588M
AUM Growth
+$588M
(-5.9%)
Cap. Flow
-$45.9M
Cap. Flow
% of AUM
-7.81%
Top 10 Holdings %
Top 10 Hldgs %
62.56%
Holding
47
New
6
Increased
12
Reduced
5
Closed
16
Top Buys
| 1 |
Scholar Rock
SRRK
|
$21.1M |
| 2 |
Merus
MRUS
|
$13M |
| 3 |
Erasca
ERAS
|
$12.9M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$12M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$11.6M |
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
$58.7M |
| 2 |
Structure Therapeutics
GPCR
|
$52.6M |
| 3 |
EyePoint Pharmaceuticals
EYPT
|
$8.74M |
| 4 |
Nuvation Bio
NUVB
|
$7.9M |
| 5 |
Praxis Precision Medicines
PRAX
|
$7.48M |
Sector Composition
| 1 | Healthcare | 99.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $96M | 15.79% | 3,006,980 | – | – |
|
2
ArriVent BioPharma
AVBP
$776M
| $54.9M | 9.03% | 2,059,387 +83,000 | +4% | +$2.21M |
|
3
Dianthus Therapeutics
DNTH
$759M
| $46M | 7.57% | 2,110,167 +363,500 | +21% | +$7.92M |
|
|
CNTA
4
Centessa Pharmaceuticals
CNTA
$2.25B
| $33.4M | 5.49% | 1,993,052 -19,000 | -0.9% | -$318K |
|
|
VRNA
5
Verona Pharma
VRNA
$9.16B
| $26.5M | 4.37% | 571,264 -1,263,936 | -69% | -$58.7M |
|
|
6
Nuvation Bio
NUVB
$1.02B
| $24.5M | 4.03% | 9,202,907 -2,968,606 | -24% | -$7.9M |
|
7
Insmed
INSM
$28.8B
| $22.9M | 3.77% | 332,000 -104,820 | -24% | -$7.24M |
|
8
Cogent Biosciences
COGT
$1.69B
| $21.6M | 3.55% | 2,763,000 +1,458,000 | +112% | +$11.4M |
|
|
9
Scholar Rock
SRRK
$3.14B
| $21.1M | 3.47% | +488,000 | New | +$21.1M |
|
10
MindMed
MNMD
$676M
| $21M | 3.46% | 3,018,000 | – | – |
|
11
Ocular Therapeutix
OCUL
$2.12B
| $20.7M | 3.41% | 2,425,000 | – | – |
|
12
Taysha Gene Therapies
TSHA
$797M
| $18.1M | 2.97% | 10,450,000 +5,877,778 | +129% | +$10.2M |
|
13
Viridian Therapeutics
VRDN
$1.5B
| $16.7M | 2.74% | 870,000 | – | – |
|
14
Gossamer Bio
GOSS
$562M
| $16.6M | 2.73% | 18,350,000 +9,162,117 | +100% | +$8.29M |
|
15
Dyne Therapeutics
DYN
$1.92B
| $15.7M | 2.59% | 668,000 +405,274 | +154% | +$9.55M |
|
16
Pharvaris
PHVS
$1.39B
| $14.9M | 2.45% | 778,000 +157,530 | +25% | +$3.02M |
|
17
Corbus Pharmaceuticals
CRBP
$115M
| $13.2M | 2.17% | 1,115,000 | – | – |
|
|
18
Merus
MRUS
$4.98B
| $13M | 2.13% | +308,000 | New | +$13M |
|
|
19
Erasca
ERAS
$445M
| $12.9M | 2.12% | +5,136,795 | New | +$12.9M |
|
20
BridgeBio Pharma
BBIO
$9.89B
| $12.1M | 1.99% | 441,600 -110,400 | -20% | -$3.03M |
|
|
21
Syndax Pharmaceuticals
SNDX
$1.41B
| $12M | 1.97% | +904,000 | New | +$12M |
|
|
22
KalVista Pharmaceuticals
KALV
$678M
| $11.6M | 1.91% | +1,370,000 | New | +$11.6M |
|
23
Unicycive Therapeutics
UNCY
$74M
| $7.94M | 1.31% | 10,000,000 +1,441,000 | +17% | +$1.14M |
|
|
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
| $7.66M | 1.26% | 4,848,802 +585,101 | +14% | +$924K |
|
25
Perspective Therapeutics
CATX
$250M
| $7.35M | 1.21% | 2,304,752 +882,528 | +62% | +$2.82M |
|